Heart failure with preserved ejection fraction shows no excess mortality in older patients: a population-matched relative survival analysis.
Christophe de Terwangne, Nassiba Menghoum, Marin Boute...
https://pubmed.ncbi.nlm.nih.gov/41495328Actively Recruiting
Phase Not Applicable
Age: 18Years - 99Years
All Genders
Healthy Volunteers
ID03197350
Characterization of Heart Failure With Preserved Ejection Fraction
Led by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Updated on 2024-02-05
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the mechanisms behind heart failure with preserved left ventricular ejection fraction (HFpEF), a common and complex form of heart failure that affects more than half of all heart failure cases. This study aims to understand how heart structure, function, and fibrosis markers change across different stages of heart failure, and how risk factors like hypertension, diabetes, obesity, and kidney problems affect the disease progression. Researchers also want to identify factors that predict outcomes for HFpEF patients by following them over time and comparing clinical data with heart imaging and biomarkers. The study involves three groups: patients with HFpEF, patients with heart failure with reduced ejection fraction (HFrEF), and healthy control subjects without heart disease. Eligible heart failure patients must be 50 years or older, have specific heart function measurements, symptoms, and recent hospitalization or elevated heart-related biomarkers. Participants will undergo cardiac magnetic resonance imaging (cMR) to assist diagnosis and evaluate heart structure and function. Control subjects will be recruited across different age decades and will have no heart risk factors or abnormalities on heart tests. Participants will be followed to assess their prognosis, including heart failure hospitalizations or deaths over a six-month period. The study collects data through imaging tests like echocardiography and MRI, blood biomarkers, and clinical evaluations to understand heart failure progression. Researchers will monitor heart function and health outcomes to determine how well imaging and biomarker measures predict future cardiovascular events. The total study duration spans several years, beginning in 2014 and ending in 2028.
CONDITIONS
Brief Title
Characterization of Heart Failure With Preserved Ejection Fraction
Who Can Participate
Age: 18Years - 99Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Controls must have no history of heart failure or previous cardiovascular disease
- Patients must have typical symptoms and signs of heart failure with New York Heart Association class II or higher
- Patients must have NT-proBNP levels greater than 350 pg/mL or have been hospitalized for heart failure within the previous 12 months
- Patients with heart failure with reduced ejection fraction must have LVEF below 40%
- Patients with heart failure with preserved ejection fraction must have LVEF of 50% or higher with signs of diastolic dysfunction
- Participants must be aged between 18 and 99 years old
You will not qualify if you...
- Severe valvular heart disease
- Infiltrative or hypertrophic cardiomyopathy
- Acute coronary syndrome within the last 30 days
- Chronic obstructive pulmonary disease classified as GOLD 3 or 4
- Congenital heart disease
- Pericardial disease
- Terminal renal failure with eGFR below 15 mL/min/1.73m² or requiring dialysis
- Atrial fibrillation with ventricular response over 140 bpm
- Severe anemia with hemoglobin below 8 g/dL
- Liver dysfunction
- Active or evolving cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Up to 1 week
Participants undergo cardiac MRI (cMR) and biomarker assessments to complete diagnosis and correlate prognostic information.
1 to 2 visits depending on assessments
Long-term Monitoring
Duration - 6 months
Participants are followed up to monitor heart failure hospitalizations and survival outcomes over 6 months.
Periodic follow-up visits during 6 months
Trial Site Locations
Total: 1 location
1
Cliniques universitaires Saint Luc
Brussels, Belgium
Actively Recruiting
Loading map...
Research Team
A
Anne-Catherine Pouleur
A
Anne Catherine Pouleur
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction.
Nassiba Menghoum, Maria Chiara Badii, Martin Leroy...
https://pubmed.ncbi.nlm.nih.gov/40121452Association of Plasma Myeloperoxidase with Inflammation and Diabetic status in HFpEF.
Sibille Lejeune, Audrey Ginion, Nassiba Menghoum...
https://pubmed.ncbi.nlm.nih.gov/39077419Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction.
Clotilde Roy, Alisson Slimani, Christophe de Meester...
https://pubmed.ncbi.nlm.nih.gov/30086783